Role of DPR in Colorectal Cancer

Publication
Video
Special ReportsGastrointestinal Cancers: mCRC (Issue 9)
Volume 1
Issue 9

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response plays an important role in the treatment of colorectal cancer.

Articles in this issue
Phase III Study of Nintedanib Could Provide a New Option for mCRC, According to Expert
Phase III Study of Nintedanib Could Provide a New Option for mCRC, According to Expert
Role of DPR in Colorectal Cancer
Role of DPR in Colorectal Cancer
Overview of the Lume 1 and 2 Trials
Overview of the Lume 1 and 2 Trials
Impact of HER2 Amplification in Colorectal Cancer
Impact of HER2 Amplification in Colorectal Cancer
Tumor Location Findings Shed Light on CALGB/SWOG 80405, FIRE-3 Discrepancy
Tumor Location Findings Shed Light on CALGB/SWOG 80405, FIRE-3 Discrepancy
ctDNA Positivity Could Spell Higher Risk of Recurrence in Early-Stage Colon Cancer
ctDNA Positivity Could Spell Higher Risk of Recurrence in Early-Stage Colon Cancer
Novel Immunotherapy Combinations on Horizon for mCRC
Novel Immunotherapy Combinations on Horizon for mCRC
SIRT Added to First-line Chemo Improves Response in Colorectal Cancer
SIRT Added to First-line Chemo Improves Response in Colorectal Cancer
Recent Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Related Content
Leronlimab Gets FDA Nod for Phase 2 Microsatellite-Stable CRC Trial

Leronlimab Gets FDA Nod for Phase 2 Microsatellite-Stable CRC Trial

Jordyn Sava
March 27th 2025
Article

A phase 2 trial will evaluate leronlimab’s safety and efficacy for the treatment of patients with microsatellite stable metastatic colorectal cancer.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Jordyn Sava;Arvind Dasari, MD, MS
November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Jonah Feldman
March 21st 2025
Article

Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.

Read More

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Michael J. Overman, MD;Nichole Tucker
July 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Listen

Truong Factors Age and High-Grade Toxicity Risk Into IO Selection in Melanoma

Truong Factors Age and High-Grade Toxicity Risk Into IO Selection in Melanoma

Targeted Oncology Staff
March 19th 2025
Article

During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma with immunotherapy.

Read More

Vokes Explores Biomarker Testing and Treatment Landscape for EGFR-Mutated Lung Cancer

Vokes Explores Biomarker Testing and Treatment Landscape for EGFR-Mutated Lung Cancer

Targeted Oncology Staff
March 18th 2025
Article

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed trials of targeted agents for EGFR-mutant lung cancer.

Read More